Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia.

"Conflict of interest statement: L. Helldin has no conflicts of interest. J. Peuskens has been a consultant for, received grants and/or research support and honoraria from, and been on the speakers’ bureaus and/or advisory boards of the following companies: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Lundbeck and Pfizer. R. Vauth has received funding for research, advisory board membership and sponsored lectures in the last 3 years from Janssen-Cilag, Otsuka, Lundbeck, Eli-Lilly and Swiss National Science Foundation. E. Sacchetti has received funding for consultancy, research, advisory board membership and sponsored lectures in the past 3 years from Lombardy Region, Italian Ministry of Education, University and Research, Angelini, AstraZeneca, Eli-Lilly, IMS Consulting Group, Innovapharma, Lundbeck, Janssen-Cilag, Otsuka, Pfizer, Roche, Rottapharm, Servier and Takeda. H. bij de Weg has no conflicts of interest. H. Herken has no conflicts of interest. M. Lahaye is a member of the Medical Affairs EMEA department of, and is employed by, Janssen-Cilag BV, The Netherlands. A. Schreiner is a full-time employee of Janssen-Cilag, Germany, and a shareholder of Johnson & Johnson."

"Funding: The study, writing, and editorial support were funded by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA."